TP53 and cancer: This strategy, already currently considered for cancer therapies could increase p53 levels thereby limiting MK polyploidization, returning the ploidy distribution to a non-thrombotic profile (Jiang and Zawacka-Pankau, 2020; Koo et al., 2022).